No Data
No Data
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. -- Barrons.com
Novo Nordisk A/S (NVO): A Bull Case Theory
Veru Surges as It Sells FC2 Female Condom Business to Private Investors
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There's a Clear Winner. -- Barrons.com
Top Gap Ups and Downs on Monday: AR, DJT, MSTR and More
Money Thrill : Not a problem... between 80 and 90 good price. You can never trust statistics 100%. There is always a margin of error. For example, the patients did not take the prescribed maximum dose. And 2 % difference is negligible. Exaggerated price reaction. I will definitely buy some more ... next days or week .